Creo Medical GroupCMEOF 53 Gross Margin % is 36.84% as of Dec. 2025, which is 20% below its 10-year median of 46.04. GuruFocus rates CMEOF with a GF Score™ of 53/100 and a GF Value™ of $0.25. The stock has 6 warning signs investors should review. Among 806 Medical Devices & Instruments companies, Creo Medical Group ranks worse than 68.24% on this metric.
The historical rank and industry rank for Creo Medical Group's Gross Margin % or its related term are showing as below:
CMEOF'
s Gross Margin % Range Over the Past 10 Years
Min: 38.46 Med: 46.04 Max: 57.5
Current: 40
During the past 11 years, the highestGross Margin % of Creo Medical Group was 57.50%. The lowest was 38.46%. And the median was 46.04%.
CMEOF's Gross Margin % is ranked worse than 68.24% of 806
companies
in the Medical Devices & Instruments industry
Industry Median: 51.985
vs CMEOF: 40.00
Creo Medical Group had a gross margin of 36.84% for the quarter that ended in Dec. 2025 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Creo Medical Group was -0.20% per year.
Creo Medical Group (OTCPK:CMEOF) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Creo Medical Group had a gross margin of 36.84% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Creo Medical Group Gross Margin % Related Terms
Creo Medical Group Gross Margin % Historical Data
* Premium members only.
The historical data trend for Creo Medical Group's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Creo Medical Group's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creo Medical Group Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Creo Medical Group's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Creo Medical Group's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Creo Medical Group (CMEOF) has a Gross Margin % of 36.84% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Creo Medical Group and its competitors. This is 20% below median its historical median of 46.04. Over the past decade, Creo Medical Group's Gross Margin % has ranged from 38.46 to 57.50. According to the industry distribution chart, Creo Medical Group ranks #550 out of 806 companies in the Medical Devices & Instruments industry, placing it in the top 68.2%.
Is Creo Medical Group's Gross Margin % too high?
Creo Medical Group's current Gross Margin % of 36.84% is 20% below median its 10-year median of 46.04. Over the past 10 years, this metric has ranged from a low of 38.46 to a high of 57.50. The Medical Devices & Instruments industry median Gross Margin % is 51.99. Creo Medical Group's value of 36.84% is 29.1% below this industry median. Based on the distribution chart, Creo Medical Group ranks #550 out of 806 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Creo Medical Group has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Creo Medical Group's Gross Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Creo Medical Group ranks #550 out of 806 companies for Gross Margin %. This places Creo Medical Group in the lower half of its industry. The industry median Gross Margin % is 51.99. Creo Medical Group's value of 36.84% is 29.1% below this benchmark. Historically, Creo Medical Group's own Gross Margin % has ranged from 38.46 to 57.50 over the past decade. While the company's 10-year median is 46.04 vs. the industry median of 51.99, Creo Medical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 51.99, based on 806 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Creo Medical Group's current Gross Margin % of 36.84% is 29.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Creo Medical Group and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 51.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creo Medical Group's current Gross Margin % is 36.84%, which is 20% below median its own 10-year median of 46.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creo Medical Group stock overvalued right now?
Creo Medical Group (CMEOF) has a current Gross Margin % of 36.84%. The stock's GF Value™ is $0.25, compared to a current price of $0.20 — trading 20% below its estimated fair value. The current Gross Margin % is 36.84%, which is 20% below median its 10-year median of 46.04 and 29.1% below the Medical Devices & Instruments industry median of 51.99. Creo Medical Group's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Creo Medical Group (CMEOF), the current Gross Margin % is 36.84% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Creo Medical Group (CMEOF) Overvalued in 2026?
Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued.
The current stock price of $0.20 is trading 20% below its estimated GF Value™ of $0.25.
Key valuation signals for CMEOF:
Gross Margin %: 36.84% (20% below median its 10-year median of 46.04)
GF Value™: $0.25 vs. price of $0.20 (20% below fair value)
Industry Position: 29.1% below the Medical Devices & Instruments median (#550 of 806)
No single metric tells the full story. See the CMEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
53GF Score
Get the complete analysis for CMEOF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMEOF has been successfully added to your 
